Announcements Trials
Browse Landscape

Phase

Phase 2 7Phase 3 3Phase 2/3 1Phase 1/2 1Phase 1 1

Status

Recruiting 5Terminated 1Not yet recruiting 1

Sponsor Class

OTHER 4INDUSTRY 3

Study Type

Interventional 7

Sponsor

Cancer Type

Breast 7

Conditions

Breast Neoplasms 7Triple Negative Breast Neoplasms 2Solid Tumors 1Ovarian Neoplasms 1Neoplasm, Residual 1Neoplasm Metastasis 1Metastatic Castration-Resistant Prostate Cancer 1Hereditary Sensory and Autonomic Neuropathies 1HER2-positive Breast Cancer 1Endometrial Neoplasms 1Colorectal Neoplasms 1Advanced Unresectable or Metastatic Solid Malignancy 1

Interventions

Trastuzumab 303Paclitaxel 256Cyclophosphamide 251Docetaxel 238Capecitabine 175Letrozole 163Carboplatin 163Doxorubicin 145Fulvestrant 144Bevacizumab 121Anastrozole 106Tamoxifen 102exemestane 94Vinorelbine 91Epirubicin 90pertuzumab 88Gemcitabine 84Lapatinib 80Albumin-Bound Paclitaxel 74Radiotherapy 71pembrolizumab 70palbociclib 64130-nm albumin-bound paclitaxel 58eribulin 56Cisplatin 55Everolimus 49pyrotinib 44Taxes 44Goserelin 43Neoadjuvant Therapy 40

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

7 trials
RecentStart dateEnrollment
Phase 2 × Breast Neoplasms × inavolisib × Clear all
NCT07054190 2026-05-26

A Study to Test Inavolisib Treatments in Participants With Early-Stage, PIK3CA-Mutated Breast Cancer

Hoffmann-La Roche

Phase 2 Recruiting
60 enrolled
Breast

Breast Neoplasms

NCT07405801 2026-05-18

A Phase II Study Evaluating the Efficacy and Safety of Inavolisib Plus Ribociclib Plus Fulvestrant Versus Placebo Plus Ribociclib Plus Fulvestrant in Participants With Advanced Breast Cancer

Hoffmann-La Roche

Phase 2 Recruiting
80 enrolled
Breast

Breast Neoplasms

NCT07368998 2026-05-11

optINAVO

Hoffmann-La Roche

Phase 2 Recruiting
80 enrolled
Breast

Breast Neoplasms

NCT05708235 2026-03-05

MiRaDoR

MedSIR

Phase 2 Recruiting
976 enrolled
Breast

Breast Neoplasms, Neoplasm, Residual

NCT07245797 2025-11-24

A Phase II, Multicenter, Open-label Study to Evaluate the Efficacy and Safety of Neoadjuvant Therapy With Inavolisib Plus Pertuzumab and Trastuzumab as Subcutaneous (PH-FDC SC) and 3-week Cycle Nab-paclitaxel for PIK3CA-mutated, HER2+, eBC

Fudan University

Phase 2 Not yet recruiting
164 enrolled
Breast

Breast Neoplasms

NCT04849364 2025-05-31

PERSEVERE

Hoosier Cancer Research Network

Phase 2 Terminated
52 enrolled 16 charts
Breast

Breast Neoplasms, Triple Negative Breast Neoplasms

NCT05332561 2025-03-20

Genomics Guided Targeted Post-neoadjuvant Therapy in Patients With Early Breast Cancer (COGNITION-GUIDE)

German Cancer Research Center

Phase 2 Recruiting
240 enrolled
Breast

Breast Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡